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Obesity is a growing health problem and causally linked to the development of type 2 diabetes mellitus (T2DM). 
T2DM is a metabolic disorder caused by peripheral insulin resistance as well as suboptimal insulin production. 
Although endogenous non-coding small microRNAs (miRNAs) have been shown to play an important role in the 
post-transcriptional repression of target genes, the implication of obesity-induced miRNAs in metabolic 
disorders particularly in the development of insulin resistance is largely unknown. Recent studies have revealed 
that saturated fatty acid (SFA) palmitate and high fat diet (HFD) significantly increase the expression of certain 
miRNAs, such as miR-29a and miR-195, in myocytes and hepatocytes. These obesity-induced miRNAs are also 
up-regulated by SFA treatment in cultured myocytes and hepatocytes. MiR-29a targets IRS-1 3’UTR directly 
and down-regulates IRS-1 expression at the post-transcriptional level. The induction of miR-29a impairs insulin 
signaling and the insulin-stimulated glucose uptake in myocytes. MiR-195 down-regulates the mRNA and 
protein expression of INSR without apparently changing IRS-1 expression in hepatocytes. The ectopic 
expression of miR-195 reduced significantly the insulin-stimulated phosphorylation of INSR and its downstream 
molecules in hepatocytes. Moreover, the ectopic expression of miR-195 reduced the insulin-stimulated glycogen 
synthesis. Taken together, these results clearly suggest that the induction of miR-29a and miR-195 by SFA are 
causally linked to the pathogenesis of insulin resistance and T2DM in obesity. These evidences suggest novel 
molecular mechanisms of insulin resistance, and implicate SFA-induced miRNAs in T2DM and metabolic 
diseases. 
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Introduction 
MicroRNAs (miRNAs) are short endogenous non-coding 
RNAs with high evolutionary sequence conservation that 
regulate gene expression at post-transcriptional level [1, 2]. 
Mature miRNAs bind to specific complementary sequences 
within the 3’ untranslated regions (3’UTRs) of the target 
genes, thereby eventually triggering either the suppression of 
translation or degradation of the target mRNAs [1, 2]. 
Although the molecular targets and roles of individual 
miRNAs are largely unknown, there is growing evidence 
suggesting that deregulated expression of miRNAs is closely 
linked to various pathological states, such as cancer, 
neurodegeneration and cardiovascular diseases [1, 3]. Since the 
first discovery that miRNA is involved actively in 
metabolism, such as amino acid catabolism [4], several recent 
publication have suggest that miRNAs play significant roles 
in metabolic homeostasis and are implicated in the 
pathogenesis of insulin resistance and type 2 diabetes 
mellitus (T2DM) [3, 5].  
Obesity is a growing public health problem worldwide, 
and the accumulation of excess lipid in non-adipose tissues 
causes lipotoxicity, which is known as dysregulation of the 
REVIEW 
RNA & DISEASE 2015; 2: e413. doi: 10.14800/rd.413; © 2015 by Won-Mo Yang, et al. 
http://www.smartscitech.com/index.php/rd 
 
Page 2 of 4 
 
cellular metabolism and apoptosis [6,7]. In particular, the 
accumulation of excess saturated fatty acid (SFA) in the 
skeletal muscle and liver has been linked to the pathogenesis 
of insulin resistance [8,9]. Insulin resistance is a state of 
reduced cellular responsiveness to insulin, and plays an 
important role in the development of T2DM, hypertension 
and metabolic diseases [8, 9]. In the skeletal muscle and liver, 
the excess SFA results in the accumulation of diacylglycerol 
and provoking oxidative stress and mitochondrial 
dysfunction, leading to dysregulation of the cellular 
metabolism and insulin resistance [9-11].  
Recently, it was hypothesized that the expression of 
certain miRNAs targeting 3’UTR of the insulin signaling 
intermediates’ mRNAs is modulated by the SFA-induced 
obesity, which participate actively in the development of 
insulin resistance [3, 5]. Moreover, the plasma or tissue levels 
of those miRNAs might be associated with the insulin 
sensitivity of humans, thereby allowing the development of 
miRNAs as potential new diagnostic and therapeutic targets 
in insulin resistance and T2DM [3, 5]. Previous our studies 
unveiled that the certain miRNAs, such as miR-29a and 
miR-195, were increased in the skeletal muscle and liver of 
high fat diet (HFD)-fed mice with insulin resistance [12,13]. 
Hence, we investigated whether these miRNAs could be 
induced by SFA, and whether these miRNAs might actively 
participate in SFA-induced insulin resistance. 
MiR-29a, which is located in human chromosome 7q32.3 
[14], is a member of the miR-29 family comprised of three 
mature forms, miR-29a, -29b and -29c [15]. Thus far, 
approximately 50 target genes of the miR-29 family 
members have been validated experimentally from thousands 
of predicted target genes [15]. However, it is unclear if and 
how miR-29a is linked to the regulation of insulin sensitivity 
in the skeletal muscle. We have found that the expression of 
miR-29a was up-regulated in the skeletal muscle, liver and 
serum of HFD-fed mice (60% kcal from fat for 14 weeks) 
[12]. In addition, the cellular treatment of SFA palmitate in 
myocytes increased the level of miR-29a expression [12]. In 
silico target analysis indicates that the insulin receptor 
substrate-1 (IRS-1) 3´UTR contains the two putative binding 
sites for miR-29a and is highly conserved in various species. 
According to the reporter gene assay, the luciferase activities 
of IRS-1 3´UTR containing the miR-29a binding site were 
reduced significantly by miR-29a, whereas the luciferase 
activities of IRS-1 3´UTR containing miR-29a binding site 
mutants were unaffected. Moreover, the ectopic expression of 
miR-29a reduced IRS-1 protein expression significantly 
without an apparent change in the IRS-1 mRNA level in 
myocytes [12]. Therefore, miR-29a targets IRS-1 3’UTR 
directly and down-regulates IRS-1 expression at the 
post-transcriptional level. Moreover, the ectopic expression 
of miR-29a reduced the insulin-stimulated tyrosine 
phosphorylation of IRS-1 and its downstream molecules, 
such as Akt2 and glycogen synthase kinase-3β (GSK3β) in 
myocytes [12]. In addition, the ectopic expression of miR-29a 
reduced the insulin-stimulated glucose uptake in myocytes 
[12]. Overall, the ectopic expression of miR-29a impairs 
insulin signaling and the insulin-stimulated glucose uptake in 
skeletal muscle cells through the post-transcriptional 
repression of IRS-1.  
The mechanisms of SFA-induced and HFD-induced 
miR-29a expression in myocytes are unclear. Nevertheless, 
several reports have suggested that the expression of 
miR-29a induced several transcription factors, such as 
NF-κB, c-Myc, CEBPA, and p53 through binding the 
miR-29a gene promoter regions [15-18]. These transcription 
factors are up-regulated in HFD-fed mice [15-18]. Therefore, 
the up-regulation of these transcription factors by SFA and 
HFD might increase the expression of miR-29a. It is 
suggested that obesity induced by SFA generates the signals 
related to oxidative stress, inflammation and ER stress, and 
activates several transcriptional factors, such as p53 and 
CEBPA. These changes might up-regulate the expression of 
miR-29a, leading to the post-transcriptional repression of 
IRS-1 and subsequent insulin resistance. 
Hsa-miR-195 is an intronic miRNA of a hypothetical 
protein, LOC284112, located on chromosome 17p13.1 [19]. 
Based on the expression profiling and target validation 
analysis, the deregulation of miR-195 expression is 
associated with multiple diseases, such as cancer, cardiac 
hypertrophy and heart failure [20]. An increase of miR-195 
expression by SFA also causes apoptosis via targeting Sirt1 
and Bcl-2 in cardiomyocytes [21]. The other report suggests 
that miR-195 expression was increased in the liver of a 
T2DM animal model, Goto-Kakizaki rat [22]. Previously, we 
have found that HFD increased the miR-195 expression in 
the liver with a concomitant decrease in insulin receptor 
(INSR) and IRS-1 protein expression, suggesting that 
miR-195 participates in the development of hepatic insulin 
resistance in diet-induced obesity (DIO) mice [13]. Moreover, 
miR-195 expression was also found to be up-regulated 
significantly in palmitate-treated hepatocytes [13]. According 
to TargetScan and PicTar analysis, the 3’UTRs of the INSR 
and IRS-1 genes contain the predicted conserved binding 
sites for miR-195. Based on the dual luciferase reporter gene 
assay, the ectopic expression of miR-195 showed a 
significant decrease in INSR mRNA concomitant with the 
substantial suppression of the INSR protein in HepG2 cells 
[13]. On the other hand, the ectopic expression of miR-195 did 
not affect the mRNA and protein levels of the insulin 
signaling molecules, such as IRS-1, Akt2 and GSK3β in 
HepG2 cells, indicating that miR-195 down-regulates the 
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mRNA and protein expression of INSR without apparently 
changing IRS-1 expression in hepatocytes [13]. Furthermore, 
the ectopic expression of antimiR-195, an antagomiR of 
miR-195, partially but significantly rescued the palmitate- 
induced suppression of INSR in HepG2 cells, indicating that 
the up-regulation of miR-195 contributes to palmitate- 
induced INSR suppression in hepatocytes [13]. Previous study 
also examined whether the up-regulation of miR-195 impairs 
insulin signaling in hepatocytes. The ectopic expression of 
miR-195 impairs the insulin-stimulated phosphorylation of 
INSR and its downstream molecules in hepatocytes [13]. 
Moreover, the ectopic expression of miR-195 decreased the 
glycogen synthesis stimulated by insulin [13]. These results 
clearly show that the up-regulation of miR-195 impairs 
insulin signaling and the insulin-stimulated glycogen 
synthesis in hepatocytes through post-transcriptional 
repression of INSR. 
The mechanisms of SFA-induced and HFD-induced 
miR-195 expression in hepatocytes are unclear. In silico 
analysis, however, suggested that several transcription factors, 
such as SREBPs, PPARs, CEBPA and p53, might bind to the 
specific sites on the miR-195 gene promoter regions. 
Because the activation of SREBPs are essential for diabetic 
hepatic steatosis and carbohydrate-induced hyper- 
triglyceridemia [23], the miR-195 level in the liver may be 
up-regulated by SFA or HFD through SREBPs activation. 
PPARs are also well-known transcription factors activated by 
HFD that have been implicated strongly in T2DM and 
metabolic syndrome [24]. Another adipogenic transcription 
factor, CEBPA, is activated by high-energy nutrients [25]. 
Furthermore, the levels of CEBPA and p53 expression are 
up-regulated in DIO mice [18, 25]. Although further study will 
be needed, the induction of miR-195 in hepatocytes might be 
triggered by the activation of certain transcription factors 
regulated by SFA or DIO.  
Over the last decade, studies focusing on the role of 
obesity-induced miRNAs in metabolism have suggested the 
strong prognostic and therapeutic importance of miRNAs in 
insulin resistance and T2DM. Previous studies have 
implicated obesity-induced miRNAs, such as miR-29a and 
miR-195, with the development of insulin resistance and 
T2DM. Because miR-29a and miR-195 can target several 
genes and each gene can be regulated by several other 
metabolic regulators, we are currently investigating the 
regulation mechanism in these miRNAs and their crosstalk 
with metabolic regulators. Such studies will help better 
understand the pathogenesis of obesity-induced insulin 
resistance and T2DM, and enable the development of 
obesity-induced miRNAs as novel diagnostic and therapeutic 
targets for diabetes. In addition, expression profiling of 
miR-29a and miR-195 in body fluids, such as plasma and 
urine, will facilitate the development of new diagnostic 
methods by differentiating between normal and diabetic 
characteristics. Moreover, obesity-induced miRNAs might 
even find applications in therapeutics as either single agents 
or in combination therapies.  
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